The study of immune inflammatory responses centers on the intricate molecular pathways that both initiate and modulate these processes. Inflammation is ...
AJMC ®: How has treatment of complement-driven diseases changed since 2007, when the first complement inhibitor, eculizumab, was approved? SMITH: The development of eculizumab followed our ...
Novel Biologics Demonstrate Targeting of Complement System to Treat Genetic Disease, Ocular Disease and Organ Transplant CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Taligen Therapeutics, a biotechnology ...
The lectin pathway is the third pathway in the complement cascade, discovered after the classical and alternative pathways. It more closely resembles the classical pathway due to similar binding ...
Complement 3 glomerulopathy (C3G) is a rare kidney disease that affects your body’s innate immune system (complement system). Complement 3 glomerulopathy (C3G) is a kidney disease that’s caused by ...
CAMBRIDGE, Mass., Dec. 10, 2024 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today announced ...
Image of blood cells. KP104 is a bifunctional, first-in-class biologic that works by selectively inhibiting the alternative and terminal pathways in the complement system. The Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results